Drugs / Jobelyn
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02240173 | Jun → Dec 2017 | schizophrenia | Federal Neuro-Psychiatric Hospital, Yaba | Unknown | No outcome recorded |
| Phase 1/2 | NCT01703104 | Jan → Mar 2012 | sickle cell disease | Lagos State University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01704794 Comparator | Apr 2013 → Apr 2014 | sickle cell disease | Lagos State University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Jobelyn | “Jobelyn is the proprietary name for the product intended to treat sickle cell disease and it is currently marketed as a nutritional supplement.” NCT01703104 ↗ |
| Action | Inhibit | “anti inflammatory effect with a selective COX 2 inhibition” NCT01704794 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “herbal nutritional supplement” NCT01704794 ↗ |